Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase II Pivotal Cohort

5-year data support the durable efficacy and manageable safety profile of olutasidenib in relapsed/refractory mutant isocitrate dehydrogenase 1 (mIDH1) AML, including heavily pretreated patients.